media – Page 2 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

【Exclusive】Cenglang BioTech Secures Tens of Millions in Financing, Strengthens Domestic Core Competitiveness, Accelerates Global Strategy

Recently, Beijing Cenglang BioTech Co., Ltd. (hereinafter referred to as “Cenglang BioTech”), a well-known enterprise in China’s flow cytometry field, announced the completion of tens of millions of yuan in financing. This round was exclusively invested by Sunshine Harmony Capital, with StarBridge Capital serving as the exclusive financial advisor. Following its financing in March 2024, Cenglang BioTech has once again gained favor from the capital market, highlighting the industry’s broad recognition of domestic high-end flow cytometry technology innovation capabilities and commercialization prospects. Industry Breakthrough: Domestic Substitution of High-End Flow Cytometry is Imperative The U.S. Department of Commerce’s “High-Parameter Flow Cytometry Export Ban,” effective January 16, 2025, has caused significant shockwaves throughout the flow cytometry industry. The ban prohibits the export to China of flow cytometry products with “26 channels or more,” “full spectrum,” and “sorting-type” specifications. This has had a considerable impact on the development of life sciences in China, ...
- Source: drugdu
- 57
- April 27, 2026
Largest Ever! India’s Sun Pharma to Acquire Organon for $11.75 Billion in All-Cash Deal, Reshaping the Global Pharmaceutical Landscape

On April 27 (today), Sun Pharmaceutical Industries Limited (together with its subsidiaries and associates, collectively referred to as “Sun Pharma” hereinafter) and Organon & Co. (“Organon” hereinafter) jointly announced the signing of a definitive acquisition agreement. Under the terms of the agreement, Sun Pharma will acquire all outstanding shares of Organon in an all-cash transaction at a price of $14.00 per share, valuing the target company at $11.75 billion. As a global healthcare enterprise, Organon was spun off from Merck & Co. as an independent company in 2021. As a global leader in women’s health, Organon boasts solid brand credibility and strong brand assets. It offers over 70 products spanning two core segments: women’s health and general medicines, with business presence across 140 countries and a robust global footprint supported by six manufacturing sites. Upholding its founding mission in core operations, the company strives to improve access to medicines and ...
- Source: drugdu
- 56
- April 27, 2026
Pantoprazole Sodium for Injection Receives FDA Approval for Marketing Authorization

On April 24, *ST Shuangcheng(002693) issued an announcement stating that the company recently received a notification from the U.S. Food and Drug Administration (FDA) that its Abbreviated New Drug Application (ANDA) for Pantoprazole Sodium for Injection has been approved for marketing by the U.S. FDA. The drug is suitable for acute upper gastrointestinal bleeding such as duodenal ulcers, gastric ulcers, acute gastric mucosal lesions, and complex gastric ulcers. This approval signifies that the company has reached the original research level in terms of safety and efficacy, demonstrating the company’s R&D and production capabilities. It also enriches the company’s international sales product pipeline and promotes the company’s internationalization strategy. In 2025, *ST Shuangcheng achieved revenue of 277 million yuan and net profit attributable to the parent company of 19.04 million yuan. https://finance.eastmoney.com/a/202604243718365410.html
- Source: drugdu
- 50
- April 27, 2026
Regeneron’s “world’s first” gene therapy for deafness approved for market launch.

Hearing loss is one of the most common sensory impairments, affecting a large number of people. According to the World Hearing Report, more than 1.5 billion people currently suffer from varying degrees of hearing loss, and this number is expected to reach nearly 2.5 billion by 2050 . On April 23 , 2026 , Regeneron officially announced that the U.S. FDA had given accelerated approval to its investigational gene therapy Otarmeni ( lunsotogene parvec-cwha ), making it the first and currently only gene therapy approved for the treatment of hereditary hearing loss, and also Regeneron’s first approved gene therapy . The FDA emphasizes that this is the first therapy to directly address the molecular root causes of hereditary hearing loss. Scientifically, this represents a significant step forward in human medicine, moving from ” symptom treatment ” to ” gene repair . ” The success of Otarmeni not only validates the ...
- Source: drugdu
- 54
- April 27, 2026
Lunan Pharmaceutical Group’s miglitol raw material received approval from India’s DCGI

Recently, Lunan Pharmaceutical Group Lunan New Era Biotechnology Co., Ltd. received a drug registration certificate for miglitol issued by the DCGI (Drug Controller General of India, the highest administrative agency in India responsible for drug regulation). This is the second approval for the new process of miglitol raw material after it was approved by the MFDS in South Korea earlier this year. India holds a significant position in the global generic drug industry, and Lunan Pharmaceutical Group has established long-term, close, and friendly cooperative relationships with many well-known Indian pharmaceutical companies. The successful completion of this registration demonstrates our company’s strong capabilities in R&D, quality control, and registration management. Miglitol is an oral hypoglycemic agent belonging to the class of alpha-glucosidase inhibitors, primarily used to treat type 2 diabetes . It works by inhibiting alpha-glucosidase on the small intestinal mucosa, thus slowing the breakdown and absorption of carbohydrates and reducing ...
- Source: drugdu
- 43
- April 27, 2026
Dongbao Pharmaceutical’s human insulin raw materials have been approved for entry into the Pakistani market

According to Tonghua Dongbao, the company’s human insulin raw material product recently received approval from the National Drug Regulatory Authority of Pakistan, marking a new step forward in its internationalization strategy as the product can now be officially supplied to the Pakistani market. This approval was achieved by the company, as a supplier of human insulin raw materials, by supporting overseas clients in completing the registration and market approval of their formulation products in Pakistan, demonstrating the overseas competitiveness of the company’s raw material products. With over two decades of experience in the insulin field, the company has built a mature and stable large-scale raw material production system and a full life-cycle quality control system, enabling it to provide reliable and continuous raw material supplies to its global partners. Pakistan bears one of the heaviest burdens of diabetes globally. Data from the International Diabetes Federation shows that in 2024, Pakistan ...
- Source: drugdu
- 39
- April 27, 2026
Smegglutide begins to fight back

GLP-1 drugs have rapidly become a core segment of the global pharmaceutical market in the past two years. For a long time, the competitive logic of these drugs was highly simplified to a single indicator: the rate of weight loss . Temerpotide, with its higher average weight loss rate demonstrated in clinical trials, has gained a significant cognitive advantage, while its pioneering drug, semaglutide, has gradually been surpassed in this dimension, allowing temerpotide to benefit from its late-mover advantage. This weight-centric assessment method has a natural advantage in terms of dissemination. Weight loss is an intuitive, quantifiable, and quickly comparable indicator, and it is also easier for patients and non-professionals to understand. However, the problem is that this indicator itself cannot distinguish the components of weight loss . Fat loss and lean body mass loss are presented together in weight data, but the two have completely different values in a ...
- Source: drugdu
- 42
- April 27, 2026
Johnson & Johnson’s “Twin Stars” of Immunization Rise

Johnson & Johnson recently released its financial results for the first quarter of 2026. In terms of overall performance, the company achieved sales of US$24.06 billion during the reporting period, representing a year-on-year increase of 9.9%. Johnson & Johnson also raised its full-year guidance: it expects full-year sales in 2026 to reach US$100.3 billion to US$101.3 billion , with a median growth rate of 7.0%. Of these, global revenue from innovative pharmaceuticals grew by 11% to $15.4 billion. Oncology remained the mainstay of performance, with revenue of $6.97 billion, a significant year-on-year increase of 22.8%. However, the immunology business is entering a period of adjustment , with revenue of $3.38 billion, a year-on-year decrease of 8.8%. Stelara, the immunology powerhouse with annual sales of tens of billions of dollars, is shrinking rapidly due to the impact of biosimilars, while Tremfya and Icotyde are emerging as new hope. 01 The Rise ...
- Source: drugdu
- 44
- April 27, 2026
【EXPERT Q&A】What is the function of a ventilator?

Drugdu.com expert’s response: Ventilators: Core Functions, Clinical Applications, and Technological Advances I. Core Functions: From Physiological Replacement to Organ Protection Ventilators achieve three primary functions through mechanical ventilation: Gas Exchange Replacement When patients cannot maintain adequate oxygenation (PaO₂ < 60 mmHg) or CO₂ elimination (PaCO₂ > 50 mmHg) due to pulmonary diseases (e.g., pneumonia, ARDS) or neuromuscular dysfunction (e.g., spinal cord injury), ventilators directly facilitate gas exchange between alveoli and capillaries by setting tidal volume, respiratory rate, and fraction of inspired oxygen (FiO₂). Example: In ARDS patients, alveolar surfactant deficiency causes widespread atelectasis. Ventilators maintain alveolar patency using positive end-expiratory pressure (PEEP), reducing intrapulmonary shunting and improving oxygenation. Respiratory Muscle Unloading During acute exacerbations of chronic obstructive pulmonary disease (COPD), airway obstruction and intrinsic PEEP increase respiratory workload by 3–5 times normal. Ventilators assume partial or full respiratory effort via positive-pressure ventilation, alleviating muscle fatigue and preventing respiratory failure progression. ...
- Source: drugdu
- 55
- April 27, 2026
Guang Sheng Tang-Neraprazole initiated a Phase I clinical trial in China for liver injury and chronic hepatitis B.

On April 23, 2026, Guang Sheng Tang initiated a Phase I clinical trial in China for nerecvir (an HBcAg inhibitor) for the indication of liver injury and chronic hepatitis B. The trial (CTR20261605), titled “Pharmacokinetics and Safety Study of GST-HG141 Tablets in Participants with Impaired and Normal Liver Function,” plans to enroll 24 subjects. The investigational drug in this clinical trial is Neratrovir. The primary endpoints include the following pharmacokinetic parameters: Cmax (maximum plasma concentration), Tmax (time to peak concentration), t1 /2 (half-life), AUC0 -t (area under the curve from dosing to the last detection time), AUC0 -∞ (area under the curve from dosing to infinity), CL/F (apparent clearance), Vz/F (apparent volume of distribution), and plasma protein binding rate. https://bydrug.pharmcube.com/news/detail/794753dd6168e510cf7df98863df6eea
- Source: drugdu
- 66
- April 24, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.